SGLT2i Pocket Guide and Infographic

Transformation of HF Care: SGLT2is as the New Pillar in HF

The American College of Cardiology (ACC) has created practical point-of-care guidance, in the form of an Infographic and a Pocket Guide, to address common clinical questions and challenges regarding the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in the management of patients with heart failure. These tools were designed to better prepare clinicians to confidently implement SGLT2is through optimal patient selection, initiation, and sequencing.

These clinician-facing tools include key information from the following clinical policies:

2023 ACC ECDP on Management of Heart Failure with Preserved Ejection Fraction
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
2021 Update to the 2017 ACC ECDP for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction